癌症相关静脉血栓形成的通路与生物标志物
本文综述癌症患者静脉血栓栓塞症(VTE)的共同通路及癌种特异性通路。白细胞、血小板及组织因子阳性(TF+)微囊泡升高均为潜在促栓因素;可溶性P-选择素被认定为一般癌症人群血栓形成的生物标志物。未来需在各癌种中检测多种标志物以判断联合预测价值。
要点
- 白细胞、血小板及TF+微囊泡升高可单独或联合增加癌症相关血栓形成。
- 可溶性P-选择素被认定为一般癌症人群癌症相关血栓形成的生物标志物。
- TF+微囊泡与VTE的关联仅在胰腺癌中观察到;脑癌中Podoplanin表达与VTE相关。
核心结论
- 癌症患者存在共同及癌种特异性的VTE通路;多种生物标志物联合可能成为VTE预测因素,未来需在各癌种中检测多种标志物以确定联合预测价值。
研究设计与样本
- 本文为综述,总结癌症患者VTE的共同通路及癌种特异性通路,未报告检索范围。
主要发现
- 白细胞、血小板及TF+微囊泡水平升高均为单独或联合增加癌症相关血栓形成的潜在因素。
- 肺癌或结直肠癌患者常出现白细胞增多;中性粒细胞可通过释放中性粒细胞胞外诱捕网增加VTE,单核细胞可表达TF。
- 胃肠道癌、肺癌、乳腺癌及卵巢癌常观察到血小板增多,可能降低VTE所需阈值。
- 可溶性P-选择素被认定为一般癌症人群癌症相关血栓形成的生物标志物,可能反映内皮激活;内皮P-选择素表达可能通过增加白细胞募集而增强VTE。
- 胰腺癌或脑癌患者研究提示PAI-1水平升高可能促进VTE;TF+微囊泡在不同类型癌症中均可见升高,但与VTE的关联仅在胰腺癌中观察到;脑癌患者Podoplanin表达与VTE相关并可能激活血小板。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer patients have an increased risk of venous thromboembolism (VTE). In this review, we summarize common and cancer type-specific pathways of VTE in cancer patients. Increased levels of leukocytes, platelets, and tissue factor-positive (TF+) microvesicles (MVs) are all potential factors that alone or in combination increase cancer-associated thrombosis. Patients with lung or colorectal cancer often exhibit leukocytosis. Neutrophils could increase VTE in cancer patients by releasing neutrophil extracellular traps whereas monocytes may express TF. Thrombocytosis is often observed in gastrointestinal, lung, breast, and ovarian cancer and this could decrease the threshold required for VTE. Soluble P-selectin has been identified as a biomarker of cancer-associated thrombosis in a general cancer population and may reflect activation of the endothelium. P-selectin expression by the endothelium may enhance VTE by increasing the recruitment of leukocytes. Studies in patients with pancreatic or brain cancer suggest that elevated levels of PAI-1 may contribute to VTE. Although elevated levels of TF+ MVs have been observed in patients with different types of cancer, an association between TF+ MVs and VTE has been observed only in pancreatic cancer. Podoplanin expression is associated with VTE in patients with brain cancer and may activate platelets. Future studies should measure multiple biomarkers in each cancer type to determine whether combinations of biomarkers can be used as predictors of VTE. A better understanding of the pathways that increase VTE in cancer patients may lead to the development of new therapies to reduce the morbidity and mortality associated with thrombosis.
引用
- Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017. PMID: 28807983. doi:10.1182/blood-2017-03-743211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。